CVT Ranexa "Black Box" Warning On Tumorigenicity Debated In FDA Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA review documents for CV Therapeutics’ Ranexa show that the Division of Cardio-Renal Drug Products proposed a "black box" warning in labeling regarding potential tumorigenicity with the angina agent.